TSLP and asthma: In vivo studies using tezepelumab to inhibit TSLP in asthma patients showed a decrease in the airway epithelial inflammatory response, including reductions in IL-33 and type 2 cytokines when faced with a viral challenge, all while preserving the body’s natural resistance to viruses.